| HS Code | 341334 |
| Product Name | Vitamin B12 1% Pharma Grade API for Tablet/Capsule/Granule/Injection |
| Active Ingredient | Cyanocobalamin (Vitamin B12) |
| Potency | 1% w/w (10,000 mcg of Vitamin B12 per gram) |
| Grade | Pharma Grade / Pharmaceutical Grade |
| Physical Form | Fine powder for pharmaceutical manufacturing |
| Appearance | Red to dark red crystalline powder; may appear pink to reddish when diluted with a carrier |
| Solubility | Freely soluble in water; sparingly soluble in alcohol; practically insoluble in acetone, chloroform and ether |
| Route Of Administration | Oral and injectable |
| Suitable Dosage Forms | Tablet, capsule, granule, and injection |
| Intended Application | Pharmaceutical API for prevention and treatment of Vitamin B12 deficiency, anemia, and nutritional supplementation |
| Storage Conditions | Store in a tight, light-protected container in a cool, dry place below 25°C |
| Shelf Life | Typically 24 months when stored under recommended conditions |
| Pharmacopoeial Compliance | Conforms to applicable pharmaceutical standards such as USP, EP, or IP |
| Handling Caution | For pharmaceutical formulation use only; use appropriate protective equipment during handling |
As an accredited Vitamin B12 1% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed double-lined polythene bags inside 25 kg fiber drums, ensuring stability and safety for pharmaceutical production. |
| Container Loading (20′ FCL) | Vitamin B12 1% Pharma Grade API loaded in 20' FCL, secured on pallets, temperature-controlled, moisture-protected for oral and injectable use. |
| Shipping | Ship in sealed, light-resistant, moisture-proof containers to protect API integrity. Transport under cool, dry conditions, avoiding excessive heat, humidity, and direct sunlight. Ensure compliance with pharmaceutical logistics regulations. Use careful handling to prevent breakage or contamination. Suitable for oral and injectable formulations; maintain proper labeling and documentation throughout transit. |
| Storage | Store in a tightly sealed original container, protected from light and moisture, in a cool, dry, well-ventilated area. Avoid exposure to excessive heat, humidity, or direct sunlight. Keep away from oxidizing agents and incompatible materials. Maintain controlled room temperature, and use clean equipment to prevent contamination. |
| Shelf Life | Shelf life is 24 months from manufacture date when stored below 25°C, protected from light and moisture. |
Direct compression with the 1% (w/w) cyanocobalamin trituration is controlled primarily by particle-size matching between the red trituration powder and the bulk excipients; when the carrier D90 exceeds 250 µm, segregation and low assay values begin to appear in the finished batch. A 1.0 mg cyanocobalamin label claim in a 250 mg core is prepared from 100 mg of the 1% trituration on dicalcium phosphate dihydrate, equivalent to 1.0 mg cyanocobalamin, combined with 112.5 mg microcrystalline cellulose PH102, 25.0 mg partially pregelatinized starch, 10.0 mg croscarmellose sodium, 1.5 mg magnesium stearate, and 1.0 mg colloidal silicon dioxide. The trituration is passed through a 40-mesh (425 µm) stainless-steel screen and blended in a 300 L bin blender at 12 rpm for 20 minutes; lubricant is screened through a 60-mesh (250 µm) screen and added for the final 3 minutes to prevent overlubrication. Tablets are compressed on a 16-station rotary press with 9.5 mm round B-tooling at 8–12 kN compression force, targeting 60–80 N hardness and friability not more than 0.8% after 100 revolutions per USP <1216>. In-process blend uniformity is checked at 10 sampling locations with an assay RSD limit of 5.0%; finished units comply with USP <905> acceptance value ≤15.0 and dissolution per USP <711> in 900 mL purified water at 37±0.5°C, Apparatus II at 50 rpm, with target Q=75% at 60 minutes. The insoluble dicalcium phosphate carrier is mildly abrasive; punch tip inspection is required every 4 hours of continuous compression at 8 kN and above. Finished tablets are packed in amber HDPE bottles with desiccant per USP <661> and placed on long-term stability under ICH Q1A(R2) at 25±2°C/60±5% RH for 24 months.
Hard-shell capsule manufacture introduces a different control surface because the dosator or dosing-disc filling mechanism must reproducibly deliver a 125 mg powder fill that contains only 1.0 mg active substance. A size 3 hard gelatin capsule for a 1.0 mg label claim is filled with 100 mg of the 1% cyanocobalamin trituration, 22.5 mg lactose monohydrate DC grade with D90 ≤100 µm, 2.0 mg sodium starch glycolate, and 0.5 mg magnesium stearate. The blend is mixed in a 200 L diffusion mixer at 10 rpm for 15 minutes, with lubricant added in the final 3 minutes; fill weight is controlled on an intermittent tamping-pin encapsulator operating at 12,000 capsules/hour, with automatic checkweigher sampling every 10 minutes and a fill weight RSD of not more than 3.0%. Tamping-pin penetration is set to 2 mm across 5 stations to avoid densifying the powder bed and segregating the dicalcium phosphate carrier from the lactose. The principal failure mode is hopper-induced stratification because the dicalcium phosphate carrier has a tapped density near 0.9–1.0 g/mL while lactose monohydrate DC grade is typically 0.6–0.7 g/mL; hopper vibration above 20 Hz can drive the coloured trituration downward and produce assay drift. Finished capsules are tested per USP <905> with acceptance value ≤15.0 and dissolution per USP <711> in 900 mL water at 37±0.5°C, Apparatus II at 50 rpm, target Q=75% at 60 minutes. Moisture content is kept below 5.0% per USP <921>; the filling suite is held at 45–50% RH and 20–22°C because gelatin brittleness increases below 45% RH and softening occurs above 60% RH. Terminal packaging in PVC/PVDC-aluminium blisters provides the required light protection for cyanocobalamin and is tested for seal integrity per USP <671>.
Wet granulation of cyanocobalamin 1% trituration is selected when a dispersible granule or dry syrup must mask the red colour of the active fraction and provide rapid release in 10–20 mL of water. A 2.0 g unit-dose granule for a 1.0 mg cyanocobalamin label claim contains 100 mg of the 1% trituration, 1.34 g sucrose crystals with D50 200 µm, 0.40 g maltodextrin DE 12, 0.10 g anhydrous citric acid, 0.05 g sodium citrate dihydrate, and 0.01 g povidone K30 retained from the binder solution. The dry blend is granulated in a top-drive high-shear mixer at impeller speed 300 rpm and chopper speed 1500 rpm for 3 minutes, using 6–8% w/w purified water containing 4% w/w povidone K30 as binder. Water addition above 8% w/w produces a dark red paste that transfers cyanocobalamin from the dicalcium phosphate carrier into solution, causing colour bleeding and assay non-uniformity after drying. The wet mass is screened through a 10-mesh (2000 µm) screen and dried in a fluidised-bed dryer at 50±2°C until loss on drying reaches 1.5–2.5% per USP <731>. Dried granules are screened to collect the 20-mesh/60-mesh fraction; material below 60-mesh contains a disproportionate share of the 1% trituration fines and is recycled back to the next granulation at not more than 10% w/w to prevent assay accumulation. Bulk density after drying is measured per USP <616> with a target range of 0.55–0.65 g/mL, tapped density 0.70–0.80 g/mL, and Hausner ratio not more than 1.25. The terminal stick-pack line uses a volumetric auger filler with 2.0 g fill weight checkweighed every 15 minutes and fill weight RSD ≤2.0%. Content uniformity of the finished sachets is evaluated per USP <905> using 10 units and acceptance value ≤15.0; dissolution is performed per USP <711> in 900 mL water at 37±0.5°C, Apparatus II at 50 rpm, with a target Q=75% at 60 minutes. Packaging is a foil-laminated stick-pack that provides moisture barrier and light protection; storage stability is assigned under ICH Q1A(R2) at 25±2°C/60±5% RH for 24 months.
| Test parameter | Applicable dosage form | Standard designation |
|---|---|---|
| Content uniformity | Tablets, capsules, granules | USP <905>, Ph. Eur. 2.9.40 |
| Dissolution | Oral solid and granule products | USP <711> Apparatus II, 900 mL purified water, 37±0.5°C |
| Loss on drying | Wet-granulated granules | USP <731> |
| Bulk/tapped density | Granules and powder blends | USP <616> |
| Microbial limits | Oral liquids and granules | USP <61> and USP <62> |
| Preservative effectiveness | Oral syrups | USP <51> |
| Sterility | Injection | USP <71> |
| Bacterial endotoxins | Injection | USP <85> |
| Subvisible particulates | Injection | USP <788> |
| Osmolality | Injection | USP <785> |
| Container closure integrity | Injection | USP <1207> |
| Chromatographic assay | All dosage forms | USP <621> HPLC |
Aqueous oral solutions prepared from the 1% cyanocobalamin predilution require a water-soluble carrier such as mannitol or maltodextrin; a dicalcium phosphate carrier forms sediment in the finished syrup and creates non-uniform dose withdrawal after shaking. A 500 µg/5 mL syrup is prepared by dissolving 1.0 g of 1% cyanocobalamin on mannitol, equivalent to 10 mg cyanocobalamin, in each 100 mL of a vehicle containing 30 g sorbitol solution 70%, 0.20 g sodium citrate dihydrate, 0.10 g anhydrous citric acid, 0.10 g sodium benzoate, and purified water q.s. The pH is adjusted to 4.5–5.0 with 0.1 N hydrochloric acid or sodium hydroxide; aqueous cyanocobalamin degradation accelerates below pH 3.0 and above pH 7.0. Mixing is performed under nitrogen in light-protected stainless steel, and the solution is passed through a 10 µm polypropylene depth filter before filling into amber PET bottles with child-resistant closures. Co-formulation with ascorbic acid above 0.1% w/w is avoided because ascorbic acid accelerates cyanocobalamin loss in aqueous media; if a multivitamin syrup is required, ascorbic acid is separated into a second container or delivered as a barrier-coated granule. The finished syrup is tested for pH, assay by USP <621> HPLC with acceptance 90.0–110.0% of label claim, preservative effectiveness per USP <51>, and microbial limits per USP <61> and USP <62>. The shelf-life is assigned under ICH Q1A(R2) at 25±2°C/60±5% RH for 24 months if assay remains at or above 90.0%.
Injectable use of the 1% predilution is constrained by carrier load rather than active-dose precision. If the 1% cyanocobalamin-on-mannitol grade is used, each 1.0 mg cyanocobalamin unit is accompanied by 99 mg mannitol, which would produce a 1 mg/mL injection containing 9.9% w/v mannitol and an osmolality far above the USP <785> physiological target of 285–310 mOsmol/kg; published data for that specific high-mannitol parenteral configuration are limited, and terminal steam sterilisation is not used because cyanocobalamin is thermolabile in aqueous solution and degradation accelerates at sterilisation temperatures. The 1% predilution is therefore limited to lower-strength parenteral products such as a 50 µg/mL cyanocobalamin infusion additive. A 1000 mL batch of 50 µg/mL cyanocobalamin injection is prepared from 5.0 g of 1% cyanocobalamin on mannitol, equivalent to 50 mg cyanocobalamin and 4.95 g mannitol, 8.0 g sodium chloride, and Water for Injection q.s., giving a calculated osmolality of approximately 300 mOsmol/kg per USP <785>. pH is adjusted to 4.5–5.5 with 0.1 N hydrochloric acid or sodium hydroxide, and the solution is blanketed with nitrogen throughout compounding. Sterile filtration is performed through a 0.22 µm PVDF membrane per USP <71> aseptic processing; the final solution is filled into amber 2 mL borosilicate glass vials with nitrogen headspace. Endotoxin testing per USP <85> uses the route-specific K/M calculation rather than a fixed universal limit; subvisible particulates per USP <788> must not exceed 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Container closure integrity is verified per USP <1207>, and release assay is by USP <621> HPLC with acceptance 90.0–110.0% of label claim.
Freeze-dried parenteral presentations are better suited to the 1% mannitol-based predilution because the carrier functions as a crystallising bulking agent and the dose per vial is low enough to avoid hyperosmolality. A 100 µg/vial product is prepared by dissolving 10 mg of 1% cyanocobalamin on mannitol, equivalent to 0.1 mg cyanocobalamin and 9.9 mg mannitol, with 1.0 mg glycine in Water for Injection q.s. 1 mL per vial. The solution is prefiltered through a 0.45 µm membrane, sterile-filtered through 0.22 µm PVDF, and filled into amber Type I glass vials. Freeze-drying proceeds with shelf freezing at −40°C for 4 hours, primary drying at −20°C and 100 mTorr for 12 hours, and secondary drying at 20°C and 50 mTorr for 4 hours; mannitol crystallisation produces a mechanically coherent cake at 10 mg/vial fill weight without the collapse that would occur with a purely amorphous system. Reconstitution with 1.0 mL Water for Injection yields a clear solution within 30 seconds; particulate matter is controlled per USP <788>, sterility per USP <71>, and bacterial endotoxins per USP <85> using the route-specific limit. Residual moisture of the cake is tested by USP <921> Karl Fischer and should be not more than 2.0% for a stable lyophile. The container closure system is verified per USP <1207>, and the vial is labelled as a single-dose lyophile requiring protection from light. Published stability data for this exact 100 µg/vial mannitol-glycine configuration are limited outside the compendial parenteral framework, so ICH Q1A(R2) bracketing protocols are required before assigning shelf-life.
Competitive Vitamin B12 1% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Vitamin B12 1% Pharma Grade API for tablet, capsule, granule, and injection applications is a dry trituration containing 10 mg/g cyanocobalamin on a pharmacopoeial carrier. The compendial active entity is cyanocobalamin, C63H88CoN14O14P, with relative molecular mass 1355.37 g/mol. The nominal active content is therefore 10,000 µg/g; a 10 µg labelled dose requires 1.0 mg of trituration. Carrier identity is not harmonized. Oral-grade triturations commonly use mannitol (Ph. Eur. 0559; USP Mannitol monograph) or dibasic calcium phosphate dihydrate (Ph. Eur. 0980; USP Dibasic Calcium Phosphate Dihydrate monograph). Injectable-compatible grades must replace calcium phosphate with a water-soluble carrier, such as mannitol or sodium chloride, because dibasic calcium phosphate dihydrate is practically insoluble in water. Manufacturer model designations such as VB12-1%-PH are internal and do not replace compendial naming.
The trituration is an intermediate, not a finished dosage form. It requires geometric dilution into a final blend or granulation before compression, encapsulation, or solution preparation. No harmonized monograph exists for a 1% cyanocobalamin trituration as a separate article; the release specification is therefore established in the finished-product dossier. Method transfer from the Ph. Eur. Cyanocobalamin monograph 0338 or the USP Cyanocobalamin monograph is used for identity and assay, with method validation under ICH Q2(R1). Published data for a harmonized assay range for the trituration is limited; acceptance limits must be justified with batch data and finished-dose uniformity testing.
In a direct comparison, the 1% trituration multiplies the dispensed mass of the active-bearing component by a factor of 100 relative to crystalline cyanocobalamin for the same label claim. A 100,000-tablet batch at 10 µg cyanocobalamin per unit requires 1.0 g of pure crystalline active but 100 g of a 1% trituration. This larger mass reduces the influence of balance readability, static charge, and micro-dispensing error; however, it increases carrier load and formulation bulk. Crystalline cyanocobalamin is water-soluble and may be used directly in injectable compounding after dissolution and sterilising filtration, whereas the 1% trituration is carrier-dependent and may be excluded from injectable use if the carrier is insoluble. The following comparison is based on mass-balance calculation rather than pharmacopoeial equivalency.
| Material system | Mass per 10 µg dose | Batch mass for 500,000 units | Injectable route | Main handling constraint |
|---|---|---|---|---|
| Crystalline cyanocobalamin | 10 µg | 5.0 g | Direct dissolution after sterilising filtration | Static charge and micro-weighing; high assay sensitivity required |
| 1% w/w trituration | 1.0 mg | 500 g | Only with water-soluble carrier and particulate clearance | Carrier flow, segregation, and loss on drying |
| 0.1% w/w trituration | 10.0 mg | 5000 g | Same carrier limits | Higher carrier load; may be used for very low-dose or paediatric formats |
For oral solid-dose manufacturing, the 1% grade is typically selected because the active entity fraction in a 100 mg tablet at 10 µg label claim is only 0.01% w/w. Direct addition of crystalline cyanocobalamin at that concentration is impractical without solution spraying or extensive geometric dilution; the 1% trituration provides a manageable intermediate and reduces the number of dilution steps. The carrier nevertheless introduces a second particle-size distribution, and segregation during transfer into the tablet press hopper must be controlled by matching carrier and diluent bulk densities. Powder flow is measured according to Ph. Eur. 2.9.36 or USP <1174>, but the limits are product-specific and not specified by monograph.
Dispensing of the 1% trituration is normally performed in an isolator or downflow booth with an analytical balance of readability 0.1 mg. At the 100 g batch mass level, the weighing tolerance is often set at ± 1.0% to avoid label claim drift. The actual amount dispensed is recorded on the batch record; assay adjustment is not permitted unless the product dossier specifically authorizes it. The carrier may absorb atmospheric moisture at relative humidity above 60%, so the material is pre-dried or used as received only after loss-on-drying testing under Ph. Eur. 2.2.32 or USP <731>.
In a direct compression line, the trituration is first sieved through a 500 µm sieve conforming to ASTM E11-20 and pre-blended with a portion of microcrystalline cellulose in a V-blender or bin blender. The pre-blend is then combined with croscarmellose sodium and colloidal silicon dioxide; magnesium stearate is added at 0.25–0.50 wt% as a final lubricant. The final blend is compressed on a rotary tablet press with forced feeder. At the low active concentration, over-lubrication above 0.5 wt% can delay disintegration beyond the product limit when tested by Ph. Eur. 2.9.1 or USP <701>, and can reduce dissolution release in USP <711> or Ph. Eur. 2.9.3 testing. Stratified blend samples are collected at the start, middle, and end of the compression run because active content can drift as fines accumulate in the feeder. Finished-dose content uniformity uses USP <905> or Ph. Eur. 2.9.40 with an acceptance value ≤ 15.0.
High-shear granulation of a 1% cyanocobalamin trituration presents a specific failure mode: active-rich fines adhere to the stainless-steel bowl wall and chopper shaft, producing low assay values in the first granule samples and active-rich pockets in the final blend. This failure is observed when the trituration is added directly to an empty high-shear mixer before the dry diluent. The corrective procedure is to build a low-shear pre-blend in a tumble blender or drum mixer, then charge the pre-blend into the high-shear granulator and rinse the bowl with a portion of the diluent. Granulation is performed with a hypromellose binder solution at addition rates controlled by pump speed; the wet mass is milled through a cone mill with a screen aperture selected between 0.8 mm and 1.5 mm, depending on sachet or tablet granule requirement. Drying in a fluid-bed dryer must be validated because mannitol-based carriers may soften and cake at elevated residual moisture. Near-infrared monitoring of blend uniformity is possible, but the NIR method must be validated against HPLC per Ph. Eur. 2.2.29 or USP <621> because the active concentration is near the method detection limit.
At-line near-infrared monitoring of low-dose B12 blends is challenging because the active chromophore concentration is below the sensitivity of many NIR probes unless the sampling area is large. Published data for cyanocobalamin triturations is limited; in practice, HPLC is used for destructive blend sampling while NIR is reserved for moisture or blend homogeneity of the carrier. If NIR is used for release, correlation to HPLC per Ph. Eur. 2.2.29 or USP <621> must be demonstrated across three independent batches.
Injectable use of a 1% cyanocobalamin trituration is limited to water-soluble carrier grades. For a target concentration of 100 µg/mL cyanocobalamin, 10 mg of trituration is required per millilitre. The dissolution vessel is purged with nitrogen because cyanocobalamin is sensitive to strong oxidizing conditions and light; dissolution in Water for Injection is followed by filtration through a 0.22 µm sterilising-grade filter. Injectable solutions must meet sub-visible particulate matter limits in Ph. Eur. 2.9.19 or USP <788> and bacterial endotoxin limits in Ph. Eur. 2.6.14 or USP <85>. The final product must also meet the cyanocobalamin injection monograph for pH, assay, and related substances. If the carrier is dibasic calcium phosphate dihydrate, injectable use is excluded; if mannitol or sodium chloride is used, tonicity and sodium content must be calculated in the final formulation because the trituration carrier contributes to electrolyte or osmolality values. Terminal steam sterilisation may require additional stability confirmation due to the heat sensitivity of cyanocobalamin; aseptic filtration is therefore commonly used.
Mannitol-based and calcium phosphate–based 1% triturations differ in density, compactibility, and disintegration behavior. Mannitol carriers generally produce lower compactibility but faster disintegration; calcium phosphate carriers increase tablet hardness and may slow dissolution if used at high levels. Compaction data for this specific trituration configuration is limited, so tabletability must be measured on a compaction simulator or rotary press across a range of main compression forces from 8 kN to 20 kN. The compendial carrier monograph controls identity, loss on drying, and microbial quality, but it does not control particle-size distribution of the trituration. Therefore, the API manufacturer must report batch-specific D90 and bulk density to the finished-product manufacturer. Segregation risk increases when the bulk density of the trituration differs from the main diluent by more than 10%; in such cases, pre-blending with a portion of the major diluent before main mixing is required. Flowability is measured by Ph. Eur. 2.9.36 or USP <1174>; a poorly flowing trituration can be improved with colloidal silicon dioxide, but glidant levels must be justified by flow index and tablet weight variation data.
Granule and sachet presentations use the 1% trituration as a dry powder or wet-granulated component. A sachet labelled at 500 µg cyanocobalamin requires 50 mg of 1% trituration per sachet, which is sufficiently large for auger filling but still small enough to require dispersion into a larger diluent. The granule is filled into light-protective aluminum foil sachets because cyanocobalamin degrades upon prolonged exposure to UV and strong visible light. Fill-weight monitoring on an auger filler should maintain a fill-weight relative standard deviation ≤ 2.0% to support dose uniformity. Particle-size distribution is determined by sieve analysis per Ph. Eur. 2.9.12 or USP <786>; the retention fraction on a 1.0 mm sieve is controlled to prevent segregation in shipping. For oral powders, dissolution or dispersion testing follows the finished-product specification rather than a general monograph; therefore, the method must be developed and validated for the specific sachet formulation.
Multivitamin tablet and capsule blends containing the 1% trituration require segregation of cyanocobalamin from aggressive reducing agents or acidic components. Ascorbic acid and certain thiamine formulations can destabilize cyanocobalamin in wet granulations and in aqueous film-coating suspensions; therefore, the trituration should be incorporated in a dry pre-blend and protected from direct contact with reactive acidic or reducing excipients. For oral solids, the use of a protective barrier coating on the B12 granule may be necessary, but the coating must not interfere with dissolution testing under USP <711> or Ph. Eur. 2.9.3. For injectable compounding, reducing-agent exposure is controlled by nitrogen blanketing and by limiting hold time between dissolution and filtration; the holding time must be justified by oxidative stability data generated under ICH Q1A(R2) photostability conditions.
Assay of the 1% trituration requires quantitative extraction of cyanocobalamin from the carrier. The extraction solvent must be validated for the specific carrier because calcium phosphate may retain cyanocobalamin by adsorption, while mannitol may produce matrix peaks that interfere with low-wavelength detection. Method validation under ICH Q2(R1) should include specificity, linearity, accuracy, precision, and range at 80%, 100%, and 120% of the label claim. Identification is confirmed by UV-visible absorption with the characteristic cyanocobalamin maximum near 361 nm, against a pharmacopoeial reference standard. For finished dosage forms, the following compendial alignment applies.
| Attribute | Test method / standard | Limit basis |
|---|---|---|
| Assay of cyanocobalamin | Ph. Eur. 2.2.29 / USP <621> HPLC | 90.0%–110.0% of 1.0% label claim |
| Identification | Ph. Eur. 0338 / USP Cyanocobalamin monograph | Matches reference standard |
| Loss on drying | Ph. Eur. 2.2.32 / USP <731> | Carrier monograph or approved CofA |
| Microbial limits for non-sterile oral use | Ph. Eur. 2.6.12, 2.6.13 / USP <61>, <62> | Harmonized acceptance criteria for non-sterile substances |
| Uniformity of dosage units | Ph. Eur. 2.9.40 / USP <905> | Acceptance value ≤ 15.0 for solid oral forms |
| Particulate matter for injectable use | Ph. Eur. 2.9.19 / USP <788> | Complies with injectable monograph |
| Bacterial endotoxins for injectable use | Ph. Eur. 2.6.14 / USP <85> | Meets parenteral monograph limit |
Compared with a 0.1% w/w trituration, the 1% grade reduces carrier mass by a factor of 10 for the same label claim, but the 0.1% grade may be preferred for very low-dose or paediatric blends where larger dispense masses are desired. Compared with a spray-dried or micronized B12 intermediate, the 1% trituration has a different particle morphology and possible segregation profile; no harmonized particle-size specification exists, and each supplier lot must be qualified. Compared with non-cyanocobalamin forms, the product is not interchangeable with hydroxocobalamin, methylcobalamin, or adenosylcobalamin without biopharmaceutical and stability data. Hydroxocobalamin differs in water solubility and light sensitivity, and methylcobalamin and adenosylcobalamin are more oxidation-sensitive coenzyme forms. Therefore, a 1% cyanocobalamin trituration is specifically defined by its label claim, carrier, and compendial active identity.
Batch release under a quality agreement should define carrier identity, assay method, residual solvents, loss on drying, microbial quality, and, for injectable grades, endotoxin and particulate matter. Published data for this specific 1% trituration configuration is limited; full qualification in the finished dosage form is required because no harmonized monograph exists for the trituration as an independent article.
